



Discovery Park Impact

Attracting New Companies and Start-ups

NEED

The state of Indiana is positioned to attract new companies and start-ups, especially those companies in the life sciences sector tapping many existing Indiana assets.

RESOLUTION

Purdue's Discovery Park is a draw for venture capitalists interested in tapping into the deep expertise and capabilities of Purdue University. The Bindley Bioscience Center offers both cutting edge instrumentation and brings together multi-disciplinary Purdue expertise to collaborate on research projects. In late 2007, Clarian Health Ventures began their Indianapolis operations and approached staff in the Bindley Bioscience Center regarding strategic relationships around biomedical investments. An opportunity arose to explore these relationships with PDS Biotechnology, a company formed around innovative liposome drug delivery technology from the University of Cincinnati. Clarian Health Ventures was interested in PDS Biotechnology and encouraged them to consider relocation to Indiana. In a partnership with the state of Indiana's Indiana Economic Development Corporation, the Bindley Bioscience Center hosted PDS Biotechnology for a visit that included introduction to the resources at Discovery Park and the Purdue Research Park. PDS Technology was impressed with the expertise of the Purdue research teams as well as the Discovery Park infrastructure that includes the Birck Nanotechnology Center. PDS Biotechnology was interested in nanotechnology fabrication capabilities, the atmosphere of collaboration, and the support for research translation found at Discovery Park and the Purdue Research Park.

IMPACTS

On January 19th, 2009, PDS Biotechnology announced the decision to relocate its Cincinnati operations to Indiana.

About PDS Biotechnology Corporation

PDS Biotechnology Corporation is a biopharmaceutical company pioneering the development of safe, simple, potent and targeted immunotherapies for the treatment of cancer and infectious diseases. Unlike typical cancer and antiviral immunotherapies, the patented nanoparticle Versamune™ technology both facilitates the uptake of disease-associated proteins and peptides by the cells of the immune system and simultaneously activates the immune system to generate a strong and specific immune response against the infected cells in the body, resulting in eradication of the cancer or viral disease. For more information about PDS Biotechnology, visit www.pdsbiotech.com.